Jay Carrigan maintains a general corporate and commercial practice, concentrating on emerging and established companies in the information technology and life sciences, including biotechnology and medical devices, industries. Within the technology sector, his clients include those in the software, computer, robotics and chemical arenas. He assists clients with technology development, technology acquisition, and licensing arrangements; strategic alliances; marketing and distribution arrangements; outsourcing and supply arrangements; and a diverse array of commercial matters. Many of his transactions involve cross-border activities and arrangements. Jay also advises private companies and investors with respect to formation and fund raising matters.
Jay’s background includes working directly in the technology industry. He served as corporate counsel at Marcam Corporation, a software vendor that delivered ERP solutions to process manufacturers. In this role, he advised and represented Marcam and its subsidiaries in structuring and negotiating transactions to acquire technology, products and services. He also provided advice regarding contractual arrangements with partners, vendors and customers in the US, Europe, Central and South America, and Asia-Pacific regions, and assisted with the implementation of a restructuring plan, including the sale of a subsidiary and the spinoff of another subsidiary.
While serving as assistant general counsel at Tufts-New England Medical Center, Jay helped establish a for-profit subsidiary to develop and market medical outcomes measuring instruments, software and related consulting services. He assisted with industry-sponsored research/licensing transactions and served as counsel to the NEMCH Investigational Review Board. Jay also represented the center and its affiliates in structuring, negotiating and documenting acquisitions of physician practices, software, computer hardware, telecommunications and medical devices.
Represented Emendo Biotherapeutics in negotiation of a collaboration and option agreement with Takeda concerning Emendo’s gene editing platform technology
Represented PathMaker Neurosystems in its agreement with WeHealth by Servier to develop and commercialize the first neuromodulation technology for non-invasive treatment of spasticity.
Represented Olix Pharmaceuticals in negotiation of a license and collaboration agreement between Olix and Théa S.A.S. for an RNA interference treatment for dry and wet age-related macular degeneration.
Represented Alexo Therapeutics Limited in structuring, negotiating and documenting in-license of CAR-T technology from Stanford University and related $35 million Series A financing from venBio, Lightstone Ventures, Stanford University, Alexandria Equities and Longevity Fund.
Represented venBio Fund, as lead investor, in the $50 million Series A financing of Precision Biosciences, Inc., a company focused on gene editing platform technology.
Abeona Therapeuticscme Packet - gene and cell therapy products for the treatment of lysosomal storage diseases
Emendo Biotherapeutics- gene editing technology
QurAlis Corporation precision therapy technology for the treatment of ALS
Sky Computers- embedded supercomputers
The George Washington University Law School, 1987, Juris Doctor, With Honors
Trinity College, 1984, Bachelor of Arts
Awards and Affiliations
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Recognized, Copyright Law, Boston, The Best Lawyers in America (2020)